Coppell-based ZS Pharma, a fomer TECH Fort Worth client, is looking to raise more funds with an $86 million initial public offering, the company said in a filing The biotech firm recently raised $55 million from some venture capital groups a few weeks back. ZS Pharma is developing a drug treatments for hyperkalemia called ZS-9, a potentially life-threatenening medical condition in which kidneys are unable to excrete potassium. Founded in 2008 in Indiana, ZS Pharma came to Texas to work with TECH Fort Worth and received a $2 million investment from the Texas Emerging Technology Firm. JP Morgan Chase and Credit Suisee are the managers of the offering. ZS Pharma would trade on the NASDAQ Global Market under the symbol “ZSPH”.